Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
10 2021
Historique:
received: 27 10 2020
accepted: 04 05 2021
pubmed: 24 5 2021
medline: 11 3 2022
entrez: 23 5 2021
Statut: ppublish

Résumé

Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC). To evaluate standard risk stratification features, develop an optimal model to identify ≥pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models. This was a collaborative retrospective study that included 1214 patients who underwent ureterorenoscopy with biopsy followed by RNU for nonmetastatic UTUC between 2000 and 2017. We performed multiple imputation of chained equations for missing data and multivariable logistic regression analysis with a stepwise selection algorithm to create the optimal predictive model. The area under the curve and a decision curve analysis were used to compare the models. Overall, 659 (54.3%) and 555 (45.7%) patients had ≤pT1N0/Nx and ≥pT2/N+ disease, respectively. In the multivariable logistic regression analysis of our model, age (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.0-1.03, p = 0.013), high-grade biopsy (OR 1.81, 95% CI 1.37-2.40, p < 0.001), biopsy cT1+ staging (OR 3.23, 95% CI 1.93-5.41, p < 0.001), preoperative hydronephrosis (OR 1.37 95% CI 1.04-1.80, p = 0.024), tumor size (OR 1.09, 95% CI 1.01-1.17, p = 0.029), invasion on imaging (OR 5.10, 95% CI 3.32-7.81, p < 0.001), and sessile architecture (OR 2.31, 95% CI 1.58-3.36, p < 0.001) were significantly associated with ≥pT2/pN+ disease. Compared with the existing models, our model had the highest performance accuracy (75% vs 66-71%) and an additional clinical net reduction (four per 100 patients). Our proposed risk-stratification model predicts the risk of harboring ≥pT2/N+ UTUC with reliable accuracy and a clinical net benefit outperforming the current risk-stratification models. We developed a risk stratification model to better identify patients for endoscopic kidney-sparing surgery in upper tract urothelial carcinoma.

Sections du résumé

BACKGROUND
Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC).
OBJECTIVE
To evaluate standard risk stratification features, develop an optimal model to identify ≥pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models.
DESIGN, SETTING, AND PARTICIPANTS
This was a collaborative retrospective study that included 1214 patients who underwent ureterorenoscopy with biopsy followed by RNU for nonmetastatic UTUC between 2000 and 2017.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
We performed multiple imputation of chained equations for missing data and multivariable logistic regression analysis with a stepwise selection algorithm to create the optimal predictive model. The area under the curve and a decision curve analysis were used to compare the models.
RESULTS AND LIMITATIONS
Overall, 659 (54.3%) and 555 (45.7%) patients had ≤pT1N0/Nx and ≥pT2/N+ disease, respectively. In the multivariable logistic regression analysis of our model, age (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.0-1.03, p = 0.013), high-grade biopsy (OR 1.81, 95% CI 1.37-2.40, p < 0.001), biopsy cT1+ staging (OR 3.23, 95% CI 1.93-5.41, p < 0.001), preoperative hydronephrosis (OR 1.37 95% CI 1.04-1.80, p = 0.024), tumor size (OR 1.09, 95% CI 1.01-1.17, p = 0.029), invasion on imaging (OR 5.10, 95% CI 3.32-7.81, p < 0.001), and sessile architecture (OR 2.31, 95% CI 1.58-3.36, p < 0.001) were significantly associated with ≥pT2/pN+ disease. Compared with the existing models, our model had the highest performance accuracy (75% vs 66-71%) and an additional clinical net reduction (four per 100 patients).
CONCLUSIONS
Our proposed risk-stratification model predicts the risk of harboring ≥pT2/N+ UTUC with reliable accuracy and a clinical net benefit outperforming the current risk-stratification models.
PATIENT SUMMARY
We developed a risk stratification model to better identify patients for endoscopic kidney-sparing surgery in upper tract urothelial carcinoma.

Identifiants

pubmed: 34023164
pii: S0302-2838(21)00328-6
doi: 10.1016/j.eururo.2021.05.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-515

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Beat Foerster (B)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.

Mohammad Abufaraj (M)

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

Surena F Matin (SF)

Department of Urology, MD Anderson Cancer Center, Houston, TX, USA.

Mounsif Azizi (M)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Surgery, Division of Urology, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Quebec, Canada.

Mohit Gupta (M)

Brady Urological Institute and Department of Urology, Johns Hopkins Medicine, Baltimore, MD, USA.

Wei-Ming Li (WM)

Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Thomas Seisen (T)

Urology, GRC 5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Timothy Clinton (T)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Evanguelos Xylinas (E)

Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.

M Carmen Mir (MC)

Instituto Valenciano de Oncologia Foundation, Valencia, Spain.

Donald Schweitzer (D)

Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Andrea Mari (A)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.

Shoji Kimura (S)

Department of Urology, Jikei University School of Medicine, Tokyo, Japan.

Marco Bandini (M)

Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Romain Mathieu (R)

Department of Urology, University of Rennes, Rennes, France.

Ja H Ku (JH)

Department of Urology, Seoul National University Hospital, Seoul, Korea.

Gautier Marcq (G)

Division of Urology, McGill University Health Center, McGill University, Montreal, Canada; Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France.

Georgi Guruli (G)

Division of Urology, VCU Health, Richmond, VA, USA.

Markus Grabbert (M)

Department of Urology, Uro-Oncology, University Hospital Cologne, Cologne, Germany.

Anna K Czech (AK)

Department of Urology, Jagiellonian University Medical College, Krakow, Poland.

Tim Muilwijk (T)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Armin Pycha (A)

Department of Urology, Provincial Hospital of Bozen, Bozen, Italy; Medical School, Sigmund Freud University, Vienna, Austria.

David D'Andrea (D)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Firas G Petros (FG)

Department of Urology, MD Anderson Cancer Center, Houston, TX, USA; Department of Urology and Kidney Transplant, The University of Toledo Medical Center and Eleanor N. Dana Cancer Center, Toledo, OH, USA.

Philippe E Spiess (PE)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.

Trinity Bivalacqua (T)

Brady Urological Institute and Department of Urology, Johns Hopkins Medicine, Baltimore, MD, USA.

Wen-Jeng Wu (WJ)

Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Morgan Rouprêt (M)

Urology, GRC 5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Laura-Maria Krabbe (LM)

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, University Hospital Muenster, Muenster, Germany.

Kees Hendricksen (K)

Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Shin Egawa (S)

Department of Urology, Jikei University School of Medicine, Tokyo, Japan.

Alberto Briganti (A)

Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Marco Moschini (M)

Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Vivien Graffeille (V)

Department of Urology, University of Rennes, Rennes, France.

Wassim Kassouf (W)

Division of Urology, McGill University Health Center, McGill University, Montreal, Canada.

Riccardo Autorino (R)

Division of Urology, VCU Health, Richmond, VA, USA.

Axel Heidenreich (A)

Department of Urology, Uro-Oncology, University Hospital Cologne, Cologne, Germany.

Piotr Chlosta (P)

Department of Urology, Jagiellonian University Medical College, Krakow, Poland.

Steven Joniau (S)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Francesco Soria (F)

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Surgical Sciences, University of Torino School of Medicine, Turin, Italy.

Phillip M Pierorazio (PM)

Brady Urological Institute and Department of Urology, Johns Hopkins Medicine, Baltimore, MD, USA.

Shahrokh F Shariat (SF)

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Electronic address: shahrokh.shariat@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH